ARTICLE SUMMARY:
Devices in the current generation of transcatheter mitral valves share one trait that the founders of 4C Medical see as a limitation: their need to be anchored within the native mitral annulus. 4C Medical has an approach unlike all the others. Its replacement valve is completely above the annulus, inside the left atrium, and it leaves the native mitral valve intact.
The mitral valve segment of the structural heart disease market has been a hotbed of investment in the past few years: some $2.3 billion has been spent on investments and acquisitions of companies designing transcatheter approaches to mitral valve repair and replacement.
